At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALLK Allakos Inc.
Pre-Market Trading 06-26 05:08:54 EDT
1.18
-0.02
-1.67%
High1.22
Low1.15
Vol827.35K
Open1.21
D1 Closing1.20
Amplitude5.42%
Mkt Cap104.48M
Tradable Cap69.82M
Total Shares88.54M
T/O974.62K
T/O Rate1.40%
Tradable Shares59.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Allakos Reveals New Corporate Strategy and Performance Insights
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.